Droperidol

Sold as Inapsine. Every FDA application for this active ingredient: 1 branded and 20 generic.

As of Nov 14, 2026, FDA lists 21 applications for Droperidol (sold as Inapsine), first approved Jun 11, 1970, with 0 new uses approved and 0 published complete response letters.

First approved: Jun 11, 1970
Applications: 21
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $1K

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Droperidol	Part D	$1K	-30%	0
DROPERIDOL	Part B	$0K	New	39

Clinical Trials

5 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk PatientsUterine Fibroids (Leiomyoma), Ovarian Tumors · Zhejiang University	Not applicable	Recruiting	Mar 18, 2026
Assessment of Drug Liking In Peri-procedural Clinical SettingsDrug Liking · Stanford University	Early phase 1	Enrolling by invitation	Jun 11, 2025
Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip ArthroplastyHip Arthroplasty, Total, Post Operative Pain, Acute · Institut Mutualiste Montsouris	Not applicable	Recruiting	May 21, 2025
Droperidol and QTc Interval Changes in ED PatientsEmergency Department Patient, QTc Intervals Changes · CHRISTUS Health	—	Recruiting	Dec 10, 2024
Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm RepairElective Surgical Procedures, Postoperative Pain · University of Crete	Phase 4	Recruiting	May 20, 2021

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Jun 11, 1970	InapsineNDA 16796 · New dosage form	Rising	26	Discontinued
Nov 17, 1986	DroperidolANDA 70992	Abraxis Pharm	3	Discontinued
Nov 17, 1986	DroperidolANDA 70993	Abraxis Pharm	1	Discontinued
Feb 29, 1988	DroperidolANDA 71981	Hospira	7	Discontinued
Apr 7, 1988	DroperidolANDA 71645	Hospira	2	Discontinued
Sep 6, 1988	DroperidolANDA 71750	Smith And Nephew	0	Discontinued
Oct 19, 1988	DroperidolANDA 72019	Igi Labs Inc	2	Discontinued
Oct 19, 1988	DroperidolANDA 72021	Igi Labs Inc	2	Discontinued
Oct 20, 1988	DroperidolANDA 72018	Astrazeneca	2	Discontinued
Oct 23, 1988	DroperidolANDA 72335	Luitpold	8	Discontinued
Oct 24, 1988	DroperidolANDA 72123	Am Regent	8	Marketed
Aug 31, 1995	DroperidolANDA 72272	Hospira	2	Discontinued
Dec 14, 2017	DroperidolANDA 208197	Hikma	0	Marketed
—	DroperidolANDA 71754	Solopak	0	Discontinued
—	DroperidolANDA 71755	Solopak	0	Discontinued
—	DroperidolANDA 71941	Quad Pharms	0	Discontinued
—	DroperidolANDA 71942	Quad Pharms	0	Discontinued
—	DroperidolANDA 72020	Igi Labs Inc	0	Discontinued
—	DroperidolANDA 73520	Watson Labs	0	Discontinued
—	DroperidolANDA 73521	Watson Labs	0	Discontinued
—	DroperidolANDA 73523	Watson Labs	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA